Loading
Life sciences · Journal article
International Journal of Molecular Sciences · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hyperinsulinemia is increasingly recognized as a systemic factor that can promote tumor progression by amplifying insulin receptor and insulin-like growth factor (IGF) signaling, reshaping cancer-cell metabolism, and influencing the tumor microenvironment. Commonly associated with obesity, type 2 diabetes, and metabolic syndrome, persistent hyperinsulinemia can enhance insulin/IGF receptor signaling and downstream PI3K–AKT–mTOR and RAS–MAPK pathways. These pathways interact with stress-response networks, including NRF2-dependent redox control and AMPK–autophagy signaling, thereby supporting metabolic plasticity under nutrient and microenvironmental stress. Hyperinsulinemia-associated signaling may increase glucose utilization, pentose phosphate pathway activity, glutaminolysis, de novo lipogenesis, and antioxidant capacity, collectively promoting anabolic growth, survival, and treatment adaptation. Metabolic remodeling extends beyond aerobic glycolysis and involves context-dependent alterations in mitochondrial function, oxidative metabolism, lactate production, and metabolic crosstalk among cancer, stromal, and immune cells. Consequently, hyperinsulinemia-associated signaling may contribute to lactate-rich, immunosuppressive tumor microenvironments, tumor progression, and heterogeneous therapeutic responses across cancer types. This review integrates experimental, epidemiological, and translational evidence linking persistent hyperinsulinemia and insulin/IGF signaling with cancer metabolic reprogramming. It critically examines strategies to reduce systemic insulin exposure, inhibit insulin/IGF signaling, or co-target tumor-specific metabolic dependencies, including the metabolic consequences of PI3K-pathway inhibition. By advancing a hyperinsulinemia-centered framework, this review identifies mechanistic gaps and translational priorities for more precise metabolic interventions in cancer.